Yes. I was treated with what was going to be called Pavarutamab, which in the study was called AMG-701. Amgen pulled the study because two other drugs were FDA approved before Amgen could get theirs out. I received it for one year. I was able to achieve MRD Negative for one month, which was great. I'm now at "small monoclonal protein detected, " and have been for almost two years. Side effects were not bad.